STRUCTURE AFFINITY RELATIONSHIP AND CHARACTERIZATION OF BENZOPORPHYRINS AS POTENT INHIBITORS OF YAP ONCOPROTEIN THROUGH IN SILICO EXPERIMENTS
Keywords:YAP oncoprotein, Benzoporphyrins
Objective: Yes activated protein (YAP) is a transcriptional coactivator and corepressor that plays a pivotal role in cell proliferation. Amplification of the YAP gene and over expression of the YAP oncoprotein are reported in various human cancer cell lines. Hence inhibition of YAP by small molecular ligands would control cell proliferation.
Methods: Autodock 4.2 was used to dock the designed ligands to the active site of YAP oncoprotein. Structure affinity relationship was carried out for 70 benzoporphyrin derivatives (SAfiR). Based on the SAfiR data, 8 benzoporphyrin derivatives were designed.
Results: 8 compounds were found to potentially inhibit YAP. Verteporfin was taken as the standard with a binding energyof -6.84 kcal/Mol.The designed compounds were found to have binding energy in the range of -8.85 kcal/mol to -7.61 kcal/mol.
Conclusion: Based on the substituent effects and reported pleiotropic property of verteporfin, 8 novel porphyrin derivatives were identified with potent inhibitory effect towards the YAP oncoprotein.Â Further virtual and high throughput approaches could potent compounds that are specifically targeted towards the YAP peptide.
Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 2014;141(8):1614-26.
Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008;22:1962-71.
Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H, et al. Structural insights into the YAP and TEAD complex. Genes Dev 2010;24:235â€“40.
Duojia Pan. The hippo signaling pathway in development and cancer. Dev Cell 2010;19(4):491-505.
Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G, et al. Promoter hypermethylation-mediated down regulation of LATS1 and LATS2 in human astrocytoma. Neurosci 2006;56:450-8.
Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann VS, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007;46:865-71.
Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-67.
Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008;68:2592-8.
Yi Liu-Chittenden, Bo Huang, Joong Sup Shim, Qian Chen, Se-Jin Lee, Robert A, et al. Genetic and pharmacological disruption of the TEADâ€“YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012;26(12):1300â€“5.
Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;5(3):195-214.
Brenke R, Kozakov D, Chuang GY, Beglov D, Hall D, Landon MR, et al. Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinf 2009;25(5):621-7.
Chi-Ho Ngan, David R Hall, Brandon Zerbe, Laurie E Grove, DimaKozakov, SandorVajda. FTSite: high accuracy detection of ligand binding sites on unbound protein structures. Bioinf 2012;28:286-7.
Wirth M, Zoete V, Michielin O, Sauer W. SwissBioisostere: a database of molecular replacements for ligand design. Nucleic Acids Res 2013;41:1137-43.
Garrett MM, David S, Goodsell, Robert SH, Ruth H, William EH, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19(14):1639-62.